298 related articles for article (PubMed ID: 20350910)
1. New treatment modalities in osteoporosis.
Canalis E
Endocr Pract; 2010; 16(5):855-63. PubMed ID: 20350910
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies for osteoporosis.
Makras P; Delaroudis S; Anastasilakis AD
Metabolism; 2015 Oct; 64(10):1199-214. PubMed ID: 26277199
[TBL] [Abstract][Full Text] [Related]
3. Potential new drug targets for osteoporosis.
Deal C
Nat Clin Pract Rheumatol; 2009 Jan; 5(1):20-7. PubMed ID: 19098925
[TBL] [Abstract][Full Text] [Related]
4. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic targets for osteoporosis: beyond denosumab.
Lim V; Clarke BL
Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of osteogenesis.
Nardone V; D'Asta F; Brandi ML
Clinics (Sao Paulo); 2014 Jun; 69(6):438-46. PubMed ID: 24964310
[TBL] [Abstract][Full Text] [Related]
7. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
8. Future therapeutic targets in osteoporosis.
Deal C
Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
[TBL] [Abstract][Full Text] [Related]
9. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis.
Toulis KA; Anastasilakis AD; Polyzos SA; Makras P
Hormones (Athens); 2011; 10(3):174-95. PubMed ID: 22001129
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis: now and the future.
Rachner TD; Khosla S; Hofbauer LC
Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prevention of osteoporosis.
Blahos J
Wien Med Wochenschr; 2007; 157(23-24):589-92. PubMed ID: 18204959
[TBL] [Abstract][Full Text] [Related]
13. Emerging anabolic treatments in osteoporosis.
Mosekilde L; Tørring O; Rejnmark L
Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
[TBL] [Abstract][Full Text] [Related]
14. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
Cosman F
Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
[TBL] [Abstract][Full Text] [Related]
15. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
16. Biological agents in management of osteoporosis.
Tella SH; Gallagher JC
Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
[TBL] [Abstract][Full Text] [Related]
17. Anabolic agents: a new chapter in the management of osteoporosis.
Khan AW; Khan A
J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
[TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of postmenopausal osteoporosis.
Tella SH; Gallagher JC
J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
[TBL] [Abstract][Full Text] [Related]
19. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.
Baron R; Hesse E
J Clin Endocrinol Metab; 2012 Feb; 97(2):311-25. PubMed ID: 22238383
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Treatment of Bone Loss.
Pang R; Xia W
Curr Pharm Des; 2017; 23(41):6298-6301. PubMed ID: 28521692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
